--- title: "Mazdutide vs Tirzepatide: Side-by-Side Comparison (2026)" description: "Compare Mazdutide vs Tirzepatide — mechanism, half-life, dose range, side effects, and live vendor pricing. Mazdutide from $79.99. Tirzepatide from $49.00." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compare", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "Mazdutide vs Tirzepatide" } ] }, { "@context": "https://schema.org", "@type": "WebPage", "name": "Mazdutide vs Tirzepatide: Side-by-Side Comparison (2026)", "description": "Compare Mazdutide vs Tirzepatide — mechanism, half-life, dose range, side effects, and live vendor pricing. Mazdutide from $79.99. Tirzepatide from $49.00. Side-by-side data from BodyHackGuide — we earn a commission on some vendor links.", "url": "https://www.bodyhackguide.co/compare/mazdutide-vs-tirzepatide", "dateModified": "2026-09-07", "isPartOf": { "@type": "WebSite", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainEntity": { "@type": "ItemList", "itemListElement": [ { "@type": "ListItem", "position": 1, "item": { "@type": "Product", "name": "Mazdutide", "description": "Mazdutide (also known as IBI362, Lilly compound LY3305677) is a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist originally discovered by Eli Lilly and exclusively licensed to Innovent Biologics in 2019 for development and commercialization in Mainland China, Hong Kong, Macau, and…", "url": "https://www.bodyhackguide.co/compound/mazdutide", "category": "Weight Loss", "offers": { "@type": "AggregateOffer", "lowPrice": "79.99", "priceCurrency": "USD", "offerCount": 1 } } }, { "@type": "ListItem", "position": 2, "item": { "@type": "Product", "name": "Tirzepatide", "description": "Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a molecular weight of 4813.45 Da and CAS number 2023788-19-2. It is a 39-amino-acid synthetic peptide based on the native GIP sequence with modifications that confer…", "url": "https://www.bodyhackguide.co/compound/tirzepatide", "category": "Metabolic & Weight Loss", "offers": { "@type": "AggregateOffer", "lowPrice": "49.00", "priceCurrency": "USD", "offerCount": 17 } } } ] } }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What's the difference between Mazdutide and Tirzepatide?", "acceptedAnswer": { "@type": "Answer", "text": "Mazdutide is a weight loss that mazdutide engages two distinct receptor systems through a single peptide molecule, each contributing to metabolic effects. glp-1 receptor agonism: similar to semaglutide and…. Tirzepatide is a metabolic & weight loss that dual glp-1 and gip receptor agonism tirzepatide simultaneously activates two incretin receptors: the glp-1 receptor and the gip receptor. while the glp-1 receptor component…. The two differ in mechanism, half-life (not reported vs ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification), and typical dose range." } }, { "@type": "Question", "name": "Which has the longer half-life, Mazdutide or Tirzepatide?", "acceptedAnswer": { "@type": "Answer", "text": "Mazdutide has a half-life of not reported. Tirzepatide has a half-life of ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification. Longer half-lives generally mean less frequent dosing but slower on/off kinetics." } }, { "@type": "Question", "name": "Which is cheaper, Mazdutide or Tirzepatide?", "acceptedAnswer": { "@type": "Answer", "text": "Current lowest live price on BodyHackGuide: Mazdutide from $79.99, Tirzepatide from $49.00. Prices are pulled from the vendor listings tracked on BHG and change frequently — see the compare tables on each compound page for the current set of offers." } }, { "@type": "Question", "name": "Can you stack Mazdutide and Tirzepatide?", "acceptedAnswer": { "@type": "Answer", "text": "Stacking depends on mechanism overlap, safety profile, and goals. Mazdutide and Tirzepatide should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds." } }, { "@type": "Question", "name": "Is mazdutide the same as retatrutide?", "acceptedAnswer": { "@type": "Answer", "text": "No. Mazdutide is a dual agonist (GLP-1 + glucagon). Retatrutide is a triple agonist (GLP-1 + GIP + glucagon). The third receptor on retatrutide adds GIP-mediated potentiation, which produces steeper weight-loss curves in trials — Phase 2 retatrutide hit 24.2% at 48 weeks vs mazdutide's ~14% at 32 weeks. Both target glucagon but retatrutide is the more aggressive intervention." } }, { "@type": "Question", "name": "Why is mazdutide approved in China but not the US?", "acceptedAnswer": { "@type": "Answer", "text": "Innovent Biologics is a Chinese biotech and ran their Phase 3 trials (DREAMS-1, DREAMS-2) primarily in Chinese populations to file with the China NMPA first. Eli Lilly has co-development rights and is responsible for US filing — that submission is expected late 2026 based on the global Phase 3 readout. Until FDA approval, mazdutide is research-use only in the US." } }, { "@type": "Question", "name": "Can mazdutide help with fatty liver?", "acceptedAnswer": { "@type": "Answer", "text": "Likely yes, more directly than tirzepatide or semaglutide. Glucagon receptor agonism drives hepatic lipolysis — DREAMS-1 sub-analysis showed mazdutide reduced liver fat content by ~50% at 32 weeks (measured via MRI proton density fat fraction). Tirzepatide and semaglutide reduce liver fat secondarily via weight loss; mazdutide hits liver fat directly through the glucagon arm. For users specifically targeting NAFLD/MASLD, mazdutide and retatrutide are the more mechanistically targeted choices." } }, { "@type": "Question", "name": "How does mazdutide's faster titration affect side effects?", "acceptedAnswer": { "@type": "Answer", "text": "Per DREAMS-1 data, the faster titration (+1 step every 2 weeks vs tirzepatide's 4 weeks) concentrates GI side effects into a shorter window — nausea peaks at weeks 2-4 instead of weeks 4-8. Total cumulative GI burden over the titration phase is similar, but it hits harder + faster. Practical adjustment: many research-use users on mazdutide slow the titration to +1 step every 3-4 weeks to flatten the side-effect curve. The trial protocol isn't a requirement." } }, { "@type": "Question", "name": "Are there cardiovascular risks with mazdutide's glucagon agonism?", "acceptedAnswer": { "@type": "Answer", "text": "Modest transient signals during titration — heart rate +3-7 bpm, occasional small transient BP elevation. No clinically meaningful MACE difference vs placebo in DREAMS-1 at 32 weeks. Long-term CV outcomes trial is not yet published. Users with uncontrolled hypertension, recent MI, or significant cardiac history should consult a clinician before starting any glucagon-arm GLP-1 (mazdutide, retatrutide). For healthy users without CV comorbidities, the signal is mild and reverses after dose stabilization." } } ] } ] --- [Skip to content](#main-content) ## Research Use Only This site is an **educational resource** for research compounds. We do **not endorse** human consumption of any compound. BodyHackGuide and **BHG Labs share common ownership**; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are **21 years of age or older** and agree to our [Terms](/terms) & [Privacy Policy](/privacy). I'm 21+ — Enter SiteLeave site [![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)BodyHackGuide ](/) [Compare](/compare)[Wiki](/wiki)[Vendors](/vendors)[Deals](/deals)[Stacks](/stack-builder)[Nootropics](/nootropics)[Tools](/tools) Learn Community Search ⌘K [Sign In](/auth?returnTo=%2Fcompare%2Fmazdutide-vs-tirzepatide) 100K+ researchers trust BodyHackGuide — Join [r/BodyHackGuide](https://reddit.com/r/bodyhackguide) 1. [Home](/) 2. [Compare](/compare) 3. Mazdutide vs Tirzepatide # Mazdutide vs Tirzepatide Side-by-side comparison of Mazdutide and Tirzepatide: mechanism, half-life, dose range, safety profile, and live vendor pricing. Updated continuously as new research and listings land. Mazdutide from $79.99 Tirzepatide from $49.00 ## Live price snapshot ### Mazdutide Current low $79.99 as of Sep 5, 2026 7-day low $79.99 30-day low $79.99 30-day change — baseline building ### Tirzepatide Current low $69.99 as of Sep 5, 2026 7-day low $69.99 30-day low $69.99 30-day change — baseline building ## Mazdutide Mazdutide (also known as IBI362, Lilly compound LY3305677) is a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist originally discovered by Eli Lilly and exclusively licensed to Innovent Biologics in 2019… **Live lowest price:** $79.99 across 1 vendor [Full Mazdutide profile](/compound/mazdutide) ## Tirzepatide Featured Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a molecular weight of 4813.45 Da and CAS number 2023788-19-2. It is a 39-amino-acid… **Live lowest price:** $49.00 across 17 vendors [Full Tirzepatide profile](/compound/tirzepatide) ## Side-by-side comparison Attribute Mazdutide Tirzepatide Category Weight Loss Metabolic & Weight Loss Research Stage Approved (China, NMPA 2025); investigational in US/EU FDA Approved Mechanism of Action Mazdutide engages two distinct receptor systems through a single peptide molecule, each contributing to metabolic effects. GLP-1 Receptor Agonism: Similar to semaglutide and liraglutide. GLP-1 binds to GLP-1 receptor (GLP1R), a Gαs-coupled G-protein-coupled… Dual GLP-1 and GIP Receptor Agonism Tirzepatide simultaneously activates two incretin receptors: the GLP-1 receptor and the GIP receptor. While the GLP-1 receptor component provides the well-established effects of GLP-1 agonism (glucose-dependent insulin… Half-Life — ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification Typical Dose Range Research doses — clinical trial protocols vary 2500 mcg (2.5 mg) starting dose, titrated every 4 weeks through 5000, 7500, 10000, 12500, to 15000 mcg (15 mg) maximum weekly dose Dosing Frequency — Once weekly subcutaneous injection Administration — Subcutaneous (weekly) Side Effects Mazdutide's side-effect profile is dominated by gastrointestinal effects similar to GLP-1 agonists, with some dual-mechanism-specific considerations from the glucagon component. Most Common Side Effects: Gastrointestinal (dose-dependent): - Nausea: 40-55% at… Mild to moderate nausea (especially at initiation), headache, fatigue, constipation or diarrhea, abdominal distension. Injection site reactions. Rare: hypoglycemia, increased heart rate, pancreatitis. Molecular Weight 4563.14 g/mol 4813.5 Da Common Vial Sizes — 5mg, 10mg, 15mg ## Price History 2 data points - VANDL Labs - Disguised Alpha ## Price History 5 data points - OF - BM - Unknown - VANDL Labs - Ion Peptide - Disguised Alpha ### Mazdutide — potential benefits - Enhanced weight loss efficacy - Improved metabolic markers - Superior glucose control - Reduced cardiovascular risk factors ### Tirzepatide — potential benefits - Mean body weight reduction of 22.5% at 72 weeks - highest of any anti-obesity medication (PMID: 35658024) - 36.2% of participants achieved greater than or equal to 25% body weight loss (PMID: 35658024) - Significant HbA1c reduction in type 2 diabetes (up to 2.4% at 40 weeks in the SURPASS-5 add-on-to-insulin trial) (PMID: 35133415) - Potentially superior lean mass preservation versus GLP-1-only agents due to GIP component - Dual incretin mechanism providing complementary metabolic benefits - Improved lipid profiles including triglycerides, LDL cholesterol, and HDL cholesterol - Reduction in waist circumference and markers of visceral adiposity (PMID: 37840095) In-depth comparison ## Mazdutide vs Tirzepatide: the long answer Mazdutide is Innovent Biologics' GLP-1 + glucagon dual agonist (no GIP component); DREAMS-1 Phase 3 (2024, ~610 Chinese adults) showed 14.4% mean body-weight loss at 6 mg weekly over 32 weeks. Tirzepatide is the FDA-approved GLP-1 + GIP dual (Mounjaro/Zepbound); SURMOUNT-1 hit 22.5% at 15 mg weekly over 72 weeks. Tirzepatide wins on raw efficacy + 4-year US safety record; mazdutide's case is shorter titration + cheaper research-use channels + glucagon-driven liver-fat clearance. Last reviewed: May 19, 2026 ### Mechanism — different second receptor, different downstream effects Both are weekly subQ injectable peptides, both target GLP-1 (slows gastric emptying, suppresses appetite, amplifies insulin secretion). The difference is the second receptor each one hits. Tirzepatide adds GIP — glucose-dependent insulinotropic polypeptide — which potentiates GLP-1 and has some direct adipose effects. Mazdutide adds glucagon receptor agonism, which raises resting energy expenditure and drives hepatic lipolysis (liver fat clearance). Practically: tirzepatide hits two appetite + insulin levers; mazdutide hits one appetite/insulin lever + one metabolic-rate/liver-fat lever. The mechanistic profile makes mazdutide more interesting for users with significant fatty liver (NAFLD/MASLD) but at the cost of slightly higher transient heart-rate elevations during titration. - **Tirzepatide:** GLP-1 + GIP dual agonist (Eli Lilly) - **Mazdutide:** GLP-1 + glucagon dual agonist (Innovent Biologics / Eli Lilly partnership) - **Glucagon effect:** +5-10% resting energy expenditure, drives hepatic lipid clearance — neither GIP nor pure GLP-1 has this ### Efficacy — DREAMS-1 vs SURMOUNT-1 Tirzepatide's SURMOUNT-1 (NEJM 2022, 2,539 adults non-Asian populations) showed 22.5% mean body-weight loss at 15 mg over 72 weeks. Mazdutide's DREAMS-1 (Lancet 2024, 610 Chinese adults with obesity) showed 14.4% at 6 mg over 32 weeks — but the curve was still descending at trial end, and a follow-on 48-week Phase 3 (DREAMS-2) is showing data approaching 18% at higher doses. Cross-trial efficacy comparison is muddy because of population differences (Chinese vs Western) and trial duration, but at equivalent titration steps, tirzepatide retains a 4-7% absolute advantage on body-weight loss. Mazdutide's edge: faster titration (8-week target vs 16-week for tirzepatide) means earlier weight-loss visibility. - **Tirzepatide @ 15 mg (72 wk):** 22.5% mean body-weight loss (SURMOUNT-1) - **Mazdutide @ 6 mg (32 wk):** 14.4% mean body-weight loss (DREAMS-1) - **DREAMS-2 trajectory:** ~18% at 48 wks at higher doses — closing the gap but not equal ### Dosing — both titrate, mazdutide gets there faster Tirzepatide standard titration: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg subQ weekly, +1 step every 4 weeks. Full titration to maintenance dose takes 20 weeks. Mazdutide titration per DREAMS protocol: 1.5 → 3 → 4.5 → 6 mg weekly, +1 step every 2 weeks. Full titration in 8 weeks. The faster ramp is a double-edged sword — earlier weight loss but more concentrated GI side-effect exposure. Reconstitution is identical (BAC water, subQ abdomen/thigh/upper arm, refrigerate). Mazdutide research-use vials run $0.50-1.50/mg in the gray market; tirzepatide research-use ran $0.30-0.60/mg before FDA enforcement reduced supply. - **Tirzepatide titration:** 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg, +1 step every 4 weeks (20 weeks total) - **Mazdutide titration:** 1.5 → 3 → 4.5 → 6 mg, +1 step every 2 weeks (8 weeks total) - **Reconstitution:** Both: BAC water, subQ once weekly; refrigerate 4-30 days ### Safety — shared GI profile, mazdutide adds modest cardiac signals GI profile is essentially identical to all GLP-1 class: nausea ~45-55%, vomiting ~15-25%, diarrhea ~15-25%. Peaks during titration, fades by week 4 of each new dose. Mazdutide's glucagon receptor agonism produces small transient cardiovascular signals — heart rate +3-7 bpm during titration, modest transient blood pressure elevation in a subset of users. The DREAMS-1 trial showed no clinically meaningful MACE difference vs placebo at 32 weeks, but long-term cardiovascular outcomes are not yet published. Tirzepatide's GIP agonism has no analogous CV signal — its 4-year post-market data shows no novel cardiovascular concerns vs other GLP-1 mono-agonists. Both carry the boxed thyroid C-cell tumor warning (rodent finding, no confirmed human signal). - **Shared GI:** Nausea ~50%, vomiting ~20%, diarrhea ~20% — class effect - **Mazdutide-specific:** Transient HR +3-7 bpm, mild transient BP elevation during titration - **Tirzepatide-specific:** No novel CV signals vs class; 4-year post-market data clean - **Shared boxed warning:** Thyroid C-cell tumor risk — contraindicated in MEN-2 or family MTC history ### Cost + access — pharmacy in US vs research-use Tirzepatide retail in 2026: Mounjaro ~$1,000/month US pharmacy, Zepbound ~$1,200/month. Insurance broad for T2D, mixed for obesity. Compounded route mostly closed after FDA enforcement late 2024. Mazdutide is approved in China (June 2025) but not yet FDA-approved in the US; the US filing is expected late 2026. Until then, mazdutide is research-use only in the US — vials sourced via gray-market channels run $0.50-1.50/mg, putting a 6 mg/wk protocol at ~$3-9/week in raw molecule cost. For US-based users seeking pharmacy access today, tirzepatide is the only option; for research-use users prioritizing cost, mazdutide is dramatically cheaper. - **Tirzepatide retail:** $1,000-1,200/mo US pharmacy; insurance varies by indication - **Mazdutide retail:** Approved in China (June 2025); US FDA filing pending — research-use only in US - **Research-use cost:** Mazdutide ~$3-9/wk at 6mg dose; tirzepatide research-use limited supply ### Who chooses which If you want pharmacy-available GLP-1+ in the US today, tirzepatide is the only legal route. If you're a research-use user comparing molecules, the case for mazdutide is faster titration (visible results by week 4-6 vs week 8-12) + cheaper supply + glucagon-driven liver-fat clearance (relevant if you have fatty liver). The case for tirzepatide is the 4% extra absolute body-weight loss at maintenance + 4-year post-market safety record + no glucagon-mediated cardiac signal. Users with significant NAFLD/MASLD lean mazdutide. Users prioritizing maximum weight loss + safety track record lean tirzepatide. Retatrutide (triple agonist: GLP-1 + GIP + glucagon) outperforms both on paper but is even further from FDA approval (Phase 3 readout expected late 2026). ## Frequently asked ### What's the difference between Mazdutide and Tirzepatide? Mazdutide is a weight loss that mazdutide engages two distinct receptor systems through a single peptide molecule, each contributing to metabolic effects. glp-1 receptor agonism: similar to semaglutide and…. Tirzepatide is a metabolic & weight loss that dual glp-1 and gip receptor agonism tirzepatide simultaneously activates two incretin receptors: the glp-1 receptor and the gip receptor. while the glp-1 receptor component…. The two differ in mechanism, half-life (not reported vs ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification), and typical dose range. ### Which has the longer half-life, Mazdutide or Tirzepatide? Mazdutide has a half-life of not reported. Tirzepatide has a half-life of ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification. Longer half-lives generally mean less frequent dosing but slower on/off kinetics. ### Which is cheaper, Mazdutide or Tirzepatide? Current lowest live price on BodyHackGuide: Mazdutide from $79.99, Tirzepatide from $49.00. Prices are pulled from the vendor listings tracked on BHG and change frequently — see the compare tables on each compound page for the current set of offers. ### Can you stack Mazdutide and Tirzepatide? Stacking depends on mechanism overlap, safety profile, and goals. Mazdutide and Tirzepatide should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds. ### Is mazdutide the same as retatrutide? No. Mazdutide is a dual agonist (GLP-1 + glucagon). Retatrutide is a triple agonist (GLP-1 + GIP + glucagon). The third receptor on retatrutide adds GIP-mediated potentiation, which produces steeper weight-loss curves in trials — Phase 2 retatrutide hit 24.2% at 48 weeks vs mazdutide's ~14% at 32 weeks. Both target glucagon but retatrutide is the more aggressive intervention. ### Why is mazdutide approved in China but not the US? Innovent Biologics is a Chinese biotech and ran their Phase 3 trials (DREAMS-1, DREAMS-2) primarily in Chinese populations to file with the China NMPA first. Eli Lilly has co-development rights and is responsible for US filing — that submission is expected late 2026 based on the global Phase 3 readout. Until FDA approval, mazdutide is research-use only in the US. ### Can mazdutide help with fatty liver? Likely yes, more directly than tirzepatide or semaglutide. Glucagon receptor agonism drives hepatic lipolysis — DREAMS-1 sub-analysis showed mazdutide reduced liver fat content by ~50% at 32 weeks (measured via MRI proton density fat fraction). Tirzepatide and semaglutide reduce liver fat secondarily via weight loss; mazdutide hits liver fat directly through the glucagon arm. For users specifically targeting NAFLD/MASLD, mazdutide and retatrutide are the more mechanistically targeted choices. ### How does mazdutide's faster titration affect side effects? Per DREAMS-1 data, the faster titration (+1 step every 2 weeks vs tirzepatide's 4 weeks) concentrates GI side effects into a shorter window — nausea peaks at weeks 2-4 instead of weeks 4-8. Total cumulative GI burden over the titration phase is similar, but it hits harder + faster. Practical adjustment: many research-use users on mazdutide slow the titration to +1 step every 3-4 weeks to flatten the side-effect curve. The trial protocol isn't a requirement. ### Are there cardiovascular risks with mazdutide's glucagon agonism? Modest transient signals during titration — heart rate +3-7 bpm, occasional small transient BP elevation. No clinically meaningful MACE difference vs placebo in DREAMS-1 at 32 weeks. Long-term CV outcomes trial is not yet published. Users with uncontrolled hypertension, recent MI, or significant cardiac history should consult a clinician before starting any glucagon-arm GLP-1 (mazdutide, retatrutide). For healthy users without CV comorbidities, the signal is mild and reverses after dose stabilization. ## See current vendor prices Live listings from the vendors we track, refreshed continuously. [Mazdutide prices](/compound/mazdutide?tab=prices) [Tirzepatide prices](/compound/tirzepatide?tab=prices) [Compare all compounds](/compare) ### Before you buy Mazdutide or Tirzepatide Check the vendor trust score. Every supplier we track is rated 0–100 on COA verification, payment transparency, shipping, reviews, and listings — one published, reproducible methodology, applied to every vendor including BHG Labs, which shares our ownership. [View Vendor Scorecard](/vendors/scorecard) ## Related comparisons [Retatrutide vs Tirzepatide](/compare/retatrutide-vs-tirzepatide)[Tirzepatide vs Semaglutide](/compare/tirzepatide-vs-semaglutide)[AOD-9604 vs Tirzepatide](/compare/aod-9604-vs-tirzepatide)[5-Amino-1MQ vs Tirzepatide](/compare/5-amino-1mq-vs-tirzepatide)[Retatrutide vs Semaglutide](/compare/retatrutide-vs-semaglutide)[Orforglipron vs Semaglutide](/compare/orforglipron-vs-semaglutide)[AOD-9604 vs Semaglutide](/compare/aod-9604-vs-semaglutide) **Research use only.** BodyHackGuide is a research and price-comparison reference. BodyHackGuide and BHG Labs share common ownership. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. We earn an affiliate commission on some outbound clicks, and every vendor is ranked on the same public, reproducible methodology. See [editorial standards](/editorial-standards) and [affiliate disclosure](/affiliate-disclosure). ![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub — compound pricing, brain health protocols, dosing tools, and vendor reviews. [support@bodyhackguide.co](mailto:support@bodyhackguide.co) [](https://discord.gg/Mhq5UdRYBA)[](https://reddit.com/r/BodyHackGuide)[](https://x.com/bodyhackguide) Explore #### Explore - [Compare prices](/compare) - [Research suppliers](/vendors) - [Deals](/deals) - [Coupons](/coupons) - [Nootropics](/nootropics) - [Brain health](/brain-health) - [Blog](/blog) - [Guides](/guides) Tools #### Tools - [Reconstitution](/tools/reconstitution) - [Dosage calculator](/tools/dosage) - [Half-life visualizer](/tools/halflife) - [COA lookup](/tools/coa) - [Cost calculator](/tools/cost-calculator) - [Stack builder](/stack-builder) - [All tools →](/tools) Trust & vendors #### Trust & vendors - [Vendor directory](/vendors) - [Trust scorecard](/vendors/scorecard) - [Get BHG verified](/vendors/get-vetted) - [Scoring methodology](/vendors/methodology) - [Peptide cheatsheet](/guides/peptide-cheat-sheet-download) Company #### Company - [About](/about) - [Affiliate disclosure](/affiliate-disclosure) - [Editorial standards](/editorial-standards) - [Creators](/creators) - [Coaches](/coaches) - [Privacy](/privacy) - [Terms](/terms) - [Full site directory →](/site-directory) **Ownership & Affiliate Disclosure:** BodyHackGuide and BHG Labs share common ownership. We rank every vendor on the same public, reproducible [methodology](/vendors/methodology), and we earn a commission from purchases made through our links at no extra cost to you. Full details in our [affiliate disclosure](/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell, distribute, or promote any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · [Terms](/terms) · [Privacy](/privacy) [Shop BHG Labs · 20% off with BHG20](https://bhglabs.co/shop/?utm_source=reddit&utm_medium=paid&utm_campaign=bhg20_bridge&utm_content=sticky_mobile_bar&ref=zmgqyxku&coupon=BHG20) hi 👋